Home > Insider Trading > Filing (0000899243-20-014188)

Filing Details

Accession Number:: 0000899243-20-014188
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-05-26 17:00:26
Reporting Period:: 2020-05-21

Accepted Time:: 2020-05-26 17:00:26
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1682852	Moderna Inc.	MRNA	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1222012	Noubar Afeyan	55 Cambridge Parkway, Suite 800E Cambridge MA 02142	Yes	No	Yes	No
1503559	Flagship Ventures Fund Iv, L.p.	55 Cambridge Parkway, Suite 800E Cambridge MA 02142	No	No	Yes	No
1508051	Flagship Ventures Fund Iv General Partner Llc	C/O Flagship Pioneering, Inc. 55 Cambridge Parkway, Suite 800E Cambridge MA 02142	Yes	No	Yes	No
1590973	Flagship Ventures Fund Iv-Rx, L.p.	55 Cambridge Parkway, Suite 800E Cambridge MA 02142	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2020-05-21	223,314	$65.77	22,603,085	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-05-21	121,771	$67.15	22,481,314	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-05-21	39,082	$68.81	22,442,232	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-05-21	20,492	$70.46	22,421,740	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-05-21	13,408	$71.51	22,408,332	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-05-21	1,933	$72.44	22,406,399	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-05-21	42,540	$65.77	6,538,226	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-05-21	23,199	$67.15	6,515,027	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-05-21	7,443	$68.81	6,507,584	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-05-21	3,900	$70.46	6,503,684	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-05-21	2,551	$71.51	6,501,133	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-05-21	367	$72.44	6,500,766	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-05-22	363,594	$69.45	22,042,805	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-05-22	56,406	$70.18	21,986,399	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-05-22	69,254	$69.45	6,431,512	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-05-22	10,746	$70.18	6,420,766	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	11,460,435	Indirect	See Footnote
Common Stock	3,924	Indirect	See Footnote
Common Stock	1,389,827	Indirect	See Footnote

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.435 to $66.425, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Shares held by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"). Flagship Ventures Fund IV General Partners LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.00 to $67.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.50 to $69.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.00 to $71.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.22 to $72.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.10 to $70.095, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.10 to $70.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Shares held by Flagship VentureLabs IV LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Shares held by Flagship Pioneering, Inc. ("Pioneering"). Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Pioneering. Each of the reporting persons except for Pioneering disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Shares held by Noubar B. Afeyan, Ph.D. Each of the reporting persons except for Noubar B. Afeyan, Ph.D. disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.